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Resistance to multiple chemotherapeutic agents is a common 
clinical problem which can arise during cancer treatment. Drug 
resistance often involves overexpression of the multidrug resis-
tance MDR1 gene, encoding P-glycoprotein (P-gp), a 170-kDa 
glycoprotein belonging to the ATP-binding cassette superfamily 
of membrane transporters. We have recently demonstrated 
apoptosis-induced, caspase-3-dependent P-gp cleavage in human 
T-lymphoblastoid CEM-R VBL100 cells. However, P-gp contain 
many aspartate residues which could be targeted by caspases other 
than caspase-3. To test whether other caspases could cleave P-gp 
in vivo, we investigated the fate of P-gp during roscovitine- and 
sangivamycin- induced apoptosis in MCF7 human breast cancer 
cells, as they lack functional caspase-3. MCF7 cells were stably 
transfected with human cDNA encoding P-gp. P-gp was cleaved 
in vitro by purified recombinant caspase-3, -6 and -7. However, 
P-gp cleavage was not detected in vivo in MCF7 cells induced 
to undergoing apoptosis by either roscovitine or sangivamycin, 
despite activation of both caspase-6 and -7. Interestingly, P-gp 
overexpressing MCF7 cells were more sensitive to either rosco-
vitine or sangivamycin than wild-type cells, suggesting a novel 
potential therapeutic strategy against P-gp overexpressing cells. 
Taken together, our results support the concept that caspase-3 is 
the only caspase responsible for in vivo cleavage of P-gp and also 
highlight small molecules which could be effective in treating 
P-gp overexpressing cancers.
Introduction
Cancer patients who undergo chemotherapy often experience 
intrinsic or acquired resistance to a wide spectrum of chemothera-
peutic agents. One type of drug resistance to anticancer compounds 
is mediated by the overexpression of the 170-kDa P-glycoprotein 
(P-gp), the product of multidrug resistance (MDR1) gene.1 P-gp is 
a transmembrane glycoprotein and a member of the ATP-binding 
cassette (ABC) superfamily of membrane transport proteins. P-gp 
works like an energy-dependent efflux pump which can extrude 
various structurally unrelated chemicals at the expense of ATP 
depletion, resulting in decrease of the intracellular cytotoxic drug 
accumulation in cancer cells.2 Remarkably, expression of P-gp has 
been documented in putative cancer stem cells.3-5
It has been reported that resistance to different drugs due to 
the expression and function of P-gp, leads to a parallel resistance 
to a number of apoptotic stimuli.6,7 It has been suggested that 
overexpression of P-gp impairs the activation of caspases,8 a 
family of proteases which play fundamental roles in apoptosis.9-13 
We recently demonstrated that in P-gp overexpressing CEM-R 
T-lymphoblastoid cells, P-gp was cleaved in vivo by caspase-3 
during apoptosis induced by a number of unrelated stimuli.14 
Subsequently, it has been suggested that P-gp cleavage primes a 
caspase-3-mediated amplification of apoptotic signaling pathways 
and could be considered as a step toward a no-return pathway 
for apoptosis in tumor cells overexpressing P-gp.15 Caspases are 
specific cysteine proteases recognizing four amino acids, named 
S4, S3, S2, S1. The preferred S3 position is an invariant glutamine 
for all mammalian caspases, while S1 is an aspartate residue. Thus, 
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specificity for caspase cleavage can be better described as X-Glu-
X-Asp.16 The cleavage site of P-gp during apoptosis has not been 
identified so far.
However, P-gp protein sequence contains over 30 aspartate resi-
dues which could act as cleavage site(s).17 It is also unclear whether 
only caspase-3 cleaves P-gp during apoptosis, or other executioner 
caspases, including caspase-6 and -7, could be involved. To address 
the issue of whether caspases other than caspase-3 could cleave 
P-gp, we took advantage of the MCF7 human breast cancer cell 
line, as these cells are devoid of functional caspase-3.18 However, 
they express other functional executioner caspases, including 
caspase-6 and -7.19 Here, we demonstrate that recombinant 
caspase-3, -6 and -7, all cleaved P-gp in vitro in lysates prepared 
from P-gp overexpressing MCF7 cells. However, when MCF7 
cells were induced to undergo apoptosis by either roscovitine or 
sangivamycin, no in vivo P-gp cleavage was detected, despite acti-
vation of both caspase-6 and -7. Therefore, our results suggest that 
caspase-3 is critical for in vivo cleavage of P-gp.
Results
In vitro caspase-dependent P-gp cleavage. Initially, we evalu-
ated P-gp expression levels in human MCF7 cells stably transfected 
with MDR1 cDNA. Western blot analysis documented P-gp 
expression (Fig. 1A). This phenotypic profile was also confirmed 
by flow cytometry (Fig. 1B). Since we previously documented 
both in vitro and in vivo caspase-3-dependent P-gp cleavage in 
CEM-R cells, we assessed the in vitro cleavage action of recom-
binant effector caspase-3, -6 and -7, using MCF7 MDR cell 
extracts. All three caspases were able to cleave P-gp, as indicated 
by the appearance of the 85-kDa cleavage product in western 
blots (Fig. 1C). However, caspase-6 and -7 were more effective 
than caspase-3.
MCF7 MDR cells are susceptible to roscovitine- and sangi-
vamycin-induced apoptosis. Since human MCF7 breast cancer 
cells are relatively resistant to conventional chemotherapy, due to 
the lack of caspase-3 activity, we exposed MCF7 cells to roscovitine 
and sangivamycin, two inhibitors which exert proapoptotic activity 
in MCF7 cells.19,25 Apoptotic cell death of MCF7 WT and MCF7 
MDR cells was documented by AnnexinV-FITC/PI staining and 
also confirmed by flow cytometric analysis of PI-stained samples 
(Fig. 2A and B). Both techniques gave similar results and high-
lighted that MCF7 MDR cells were significantly (p < 0.05) more 
sensitive to the inhibitors than MCF7 WT cells.
Lack of caspase-dependent in vivo P-gp cleavage in response 
to roscovitive and sangivamycin. Western blot analysis docu-
mented that in MCF7 MDR cells, there was no in vivo P-gp 
cleavage in response to either roscovitine or sangivamycin (Fig. 
2C), in spite of the activation of both caspase-6 and -7 (Fig. 2D). 
Caspase-7 activation was demonstrated by the appearance of its 
20-kDa cleaved product, while caspase-6 activation was observed 
by the decrease of its native form. Interestingly, caspase inhibitors 
decreased caspase activation, suggesting that caspase-6 and -7 could 
cleave each other. Surprisingly, both roscovitine and sangivamycin, 
caused an increase in full length P-gp, which was strongly opposed 
by the caspase 6-inhibitor and, to a lesser extent, by the caspase 
7-inhibitor (Fig. 2C). Both caspase inhibitors prevented apoptotic 
cell death (not shown).
P-gp gene expression analysis. To investigate if the increase in 
full length P-gp occurred as a result of increased gene expression, 
we performed Real Time RT-PCR analysis (Fig. 3). P-gp mRNA 
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Figure 1. Expression and in vitro cleavage of P-gp in MCF7 MDR cells. (A) western blot analysis documenting expression of P-gp in stably transfected 
MCF7 MDR cells. MCF7 WT: parental cells. Forty μg of proteins were loaded per lane. Antibody to β-tubulin demonstrated equal loading. (B) flow 
cytometric analysis. Cells were stained for surface P-gp using a monoclonal antibody conjugated to PE. At least 10,000 events were analyzed. (C) 
western blot analysis demonstrating in vitro cleavage of P-gp by purified recombinant human capsase-3, -6 and -7. Antibody to β-tubulin demonstrated 
equal loading. In (A and C), molecular weights are indicated at left.
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Resistance to apoptotic stimuli has been reported frequently in 
MCF7 cells,27 thus apoptosis was induced with two non-P-gp 
substrates, proapoptotic drugs, roscovitine and sangivamycin. 
Roscovitine, an olomoucine-related purine flavopiridol, acts as 
a potent inhibitor for the activity of cyclin-dependent kinase 
(CDK), CDK1, CDK2, CDK5 and CDK7. Roscovitine arrested 
human MCF7 cancer cells in the G2/M phase of the cell cycle 
and concomitantly induced apoptosis.25 Sangivamycin, a protein 
kinase C inhibitor, displayed a cytotoxic effect in multidrug-resis-
tant MCF7 cells, causing massive apoptotic cell death, probably via 
activation of caspase-6, -7 and -9.19
In MCF7 MDR cells, both roscovitine and sangivamycin 
induced apoptosis, through the activation of caspase-6 and -7, 
suggesting loss of caspase-3 is compensated by the activation of 
other executioner caspases.19 In our hands the activation of these 
executioner caspases was sufficient to induce MCF7 MDR to 
undergo apoptosis, but did not lead to the characteristic in vivo 
P-gp cleavage we previously observed in apoptotic lymphoblastoid 
CEM-R cells (i.e., the 85-kDa fragment formation). Therefore, the 
roscovitine- and sangivamycin-activated apoptotic pathways, were 
not able to affect P-gp integrity in MCF7 MDR cells. In contrast, 
when MCF7 MDR cell extracts were incubated in vitro with 
recombinant caspase-3, -6 or -7, P-gp was cleaved, and we detected 
the typical 85 kDa P-gp-cleavage product. Although it is clear that 
level increased as a result of sangivamycin treatment and decreased 
in samples pre-incubated with either caspase 6- or caspase-7 
inhibitor. In contrast, at 24 hr of roscovitine treatment a marked 
decrease in P-gp mRNA was observed, which was not prevented by 
either caspase 6- or caspase 7-inhibitor (Fig. 3).
Discussion
In tumor cells, apoptotic pathways are frequently deregulated 
due to inactivation or downregulation of pro-apoptotic genes, 
including caspase-3.26 Indeed, a significant majority of human 
breast tumors lack caspase-3 expression, suggesting that loss of 
caspase-3 may represent an important cell survival mechanism in 
breast cancer patients.27 Moreover, it is established that in rosco-
vitine-treated MCF7 breast carcinoma cells, different apoptotic 
pathways are initialized depending on the status of caspase-3.25 
Recently, it has been proposed that a proapoptotic self-enhancing 
mechanism, depending on caspase-3 cleavage of P-gp, regulated 
apoptosis in a mithocondrial-dependent manner.15
Caspase-3 deficient MCF7 cells were chosen as an optimal 
model to test the hypothesis that caspase-3 activation in vivo is 
pivotal to apoptotic P-gp cleavage in P-pg overexpressing cells. 
Because pharmacological selection of cell lines expressing P-gp 
could cause genetic modifications, thus affecting cell sensitivity to 
death stimuli, MCF7 cells were transduced with MDR1 cDNA. 
Figure 2. Roscovitine and sangivamycin are proapoptotic in MCF7 cells. (A and B) Annexin V-FITC/PI staining and cell cycle analysis of MCF7 cells 
treated with either roscovitine or sangivamycin. CTR, Control (untreated) cells. At least 10,000 events were analyzed. In both (A and B), one repre-
sentative of three separate experiments is shown. In (A), the percentage of early (lower right quadrant) and late (upper right quadrant) apoptotic cells 
are indicated. In (B), the percentage of sub-G0/G1 cells is highlighted. The differences between MCF7 WT and MCF7 MDR documented in (A and B) 
were found significant (p < 0.05), when statistically analyzed. (C) western blot analysis for P-gp expression in samples treated with either roscovitine 
or sangivamycin. (D) western blot analysis for caspase-6 and -7 in samples treated with either roscovitine or sangivamycin. In both (C and D), 40 μg 
of protein were loaded per lane, and antibody to β-tubulin demonstrated equal loading. The blots in (C and D) are representative of three separate 
experiments. Molecular weights are indicated at left.
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10% fetal bovine serum, and 5 mM L-glutamine at 37°C. For 
apoptosis induction, cells were treated with either roscovitine 
(30 μM, Sigma-Aldrich Co., St. Louis, MO, USA) for 24 hr, or 
with sangivamycin (5 μM, Calbiochem, La Jolla, CA, USA) for 
16 hr. In some experiments, cells, prior to apoptosis induction 
were preincubated for two hr with 40 μM of either caspase-3/7 
inhibitor I or Z-VEID-FMK (a caspase-6 inhibitor), both from 
Calbiochem.
Cell transfection. The full length 3.843 Kb cDNA for human 
MDR1,20 was amplified by PCR using Accuprime Taq DNA poly-
merase (Invitrogen, Carlsbad, CA, USA) and cloned into BamHI/
XbAI sites of the pcDNA 3.0 (Invitrogen) expression vector into 
using the following primers: 5'-CGC GGA TCC GCG ATG GAT 
CTT GAA GGG GAC CG-3' and 5'-GCT CTA GAG CTC ACT 
GGC GCT TTG TTC CAG-3'. MCF7 cells were electroporated 
using the Cell Line Nucleofector Kit V (Amaxa Instrumentation 
Laboratories, Koln, Germany) following the manufacturer’s instruc-
tions. Selection of the stable MCF7 MDR1-overexpressing clone 
was performed in the presence of G418 (2 mg/ml). After three 
weeks of selection, cell surface expression of P-gp was detected 
by flow cytometry using phycoerythrin (PE)-conjugated anti-P-
gp monoclonal antibody (BD Biosciences Pharmingen, Milan, 
Italy)14 After selection, positive cultures (thereafter named MCF7 
MDR) were routinely maintained in 800 μg/ml G418.
In vitro P-gp cleavage. Cells were lysed in caspase lysis buffer 
(12.5 mM Hepes-NaOH, pH 7.4, 10% sucrose, 0.1% CHAPS, 
2 mM EDTA, 5 mM DTT). Samples were incubated on ice for 
1 hr, passed five times trough a 26 gauge needle, and then centri-
roscovitine and sangivamycin were proapop-
totic in MCF7 MDR cells, they also increased 
expression of full length P-gp, presumably in a 
caspase-dependent manner. In fact, pre-treat-
ment with caspase-6 or -7 inhibitors, resulted in 
a decreased expression of full length P-gp.
It has been demonstrated that in MCF7 cells, 
roscovitine induced a site-specific phosphoryla-
tion of p53 protein on Ser46 and its accumulation 
in the nucleus where it could regulate P-gp 
expression25 In addition, sangivamicyn, through 
c-Jun N-terminal kinase (JNK) pathway activa-
tion19 may modulate p53 and P-gp expression. 
Accordingly, we would have expected a reduc-
tion in P-gp expression in samples treated with 
sangivamycin, as JNK has been reported to 
negatively affect P-gp gene expression through 
c-Jun.23,28 Only in sangivamicyn-treated MCF7 
MDR cells were the changes in P-gp mRNA 
expression correlated to changes in P-gp protein 
levels. The promoter of the MDR1 gene harbors 
stress-responsive elements, which could be 
induced by cytostatic drugs.29 In MCF7 MDR 
cells, sangivamycin inhibited cell cycle progres-
sion by inducing an arrest in the G1 phase 
(data not shown). Therefore, we speculate that 
sangivamycin could lead to MDR1 gene tran-
scription through a mechanism similar to that 
of cytostatic drugs. In contrast, in roscovitine-treated MCF7 MDR 
cells this trend was not observed. Therefore, in this case, increased 
P-gp protein expression could be due to other mechanisms, such 
as protein stabilization and increased half-life.
An interesting finding is that MCF7 MDR cells were more 
sensitive to both roscovitine and sangivamycin than parental cells. 
This observation could be clinically relevant, as roscovitine is now 
undergoing clinical trials for cancer patients.30-32
In conclusion, our findings demonstrate that caspase-3 plays a 
fundamental role in vivo in apoptotic P-gp cleavage and that, in 
cases where caspase-3 is lacking, P-gp cleavage could not occur, 
in spite of caspase-6 and -7 activation, whereas in vitro both 
caspase-6 and -7 could substitute for caspase-3. The reasons for 
this phenomenon are at present unknown, but they may be related 
to a different subcellular localization of capase-6 and -7 relative 
to P-gp, which would preclude them from cleaving P-gp in vivo. 
Future investigations should clarify this issue. However, in P-gp 
overexpressing cells, apoptosis did take place even if P-gp was not 
cleaved by caspases, indicating that cleavage itself is not a prereq-
uisite for cell death to occur.
Materials and Methods
Cell culture and induction of apoptosis. The parental human 
mammary adenocarcinoma cell line MCF7 (MCF7 WT) was 
purchased from the American Type Culture Collection (Manassas, 
VA, USA). Cells were grown as a monolayer up to 60–70% 
confluence in Minimum Essential Medium supplemented with 
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Figure 3. Effects of roscovitine and sangivamycin on P-gp mRNA expression levels. Real-Time 
RT-PCR was performed as described in Materials and Methods. GAPDH was used as the house-
keeping gene. One representative of three different experiments which gave similar results is 
presented.
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fuged for 15 min at 4°C at 17,000 xg. Protein concentration in 
the supernatants was determined by standard techniques. Samples 
(300 μg of protein) were incubated for 4 hr at 37°C in the presence 
of recombinant human caspase-3, -6 or -7 (50 Units/each, all from 
from Calbiochem), as reported elsewhere.14 Electrophoresis sample 
buffer was then added to stop the reaction.
Preparation of whole cell lysates and western blot analysis. 
Cells were lysed as described elsewhere,21 and proteins were resolved 
by SDS-PAGE and transferred onto nitrocellulose membranes, as 
previously reported.22 Membranes were incubated overnight at 
4°C with the following antibodies: mouse monoclonal antibody to 
P-gp (clone F4, Sigma-Aldrich), rabbit antibody to either caspase-6 
or -7 (Cell Signaling Technology, Danvers, MA, USA), mouse 
monoclonal antibody to β-tubulin (Sigma-Aldrich). Nitrocellulose 
membranes were then processed as described elsewhere.23
Flow cytometric analysis of cell cycle and apoptosis. Cell cycle 
distribution was analyzed by flow cytometric analysis of samples 
stained with propidium iodide (PI, 20 μg/ml) for 0.5 hr. At least 
10,000 events/sample were recorded. Apoptosis was detected using 
an Annexin V-FITC/PI kit (Bender MedSystems, Vienna, Austria) 
following the manufacturer’s instructions. Samples were then 
analyzed by flow cytometry using an XL flow cytometer (Beckman 
Coulter, Miami, FL, USA).24
Real-time RT-PCR. To analyze and quantify the levels of 
MDR1 gene expression, we used a TaqMan isoform-specific probe 
(Assay n° Hs00184491_m1, Applied Biosystems, Foster City, CA). 
Reactions were run on the ABI Prism 7300 sequence detection 
system (Applied Biosystems) with the following conditions: 50°C 
for 2 min, 95°C for 10 min followed by 40 cycles of 95°C for 15 
s and 60°C for 1 min. Glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) was used as the housekeeping gene. Quantification 
analysis was performed using the ΔΔCt method and statistically 
analyzed by GraphPad Prism 4.0 software.
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